Literature DB >> 7543770

Tumour vasculature--a potential therapeutic target.

C T Baillie1, M C Winslet, N J Bradley.   

Abstract

The tumour vasculature is vital for the establishment, growth and metastasis of solid tumours. Its physiological properties limit the effectiveness of conventional anti-cancer strategies. Therapeutic approaches directed at the tumour vasculature are reviewed, suggesting the potential of anti-angiogenesis and the targeting of vascular proliferation antigens as cancer treatments.

Entities:  

Mesh：

Year:  1995        PMID： 7543770      PMCID： PMC2034004          DOI： 10.1038/bjc.1995.323

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  143 in total

1.  Tumor growth and neovascularization: an experimental model using the rabbit cornea.

Authors:  M A Gimbrone; R S Cotran; S B Leapman; J Folkman
Journal:  J Natl Cancer Inst       Date:  1974-02       Impact factor: 13.506

2.  Endothelium stimulating factor from Walker carcinoma cells. Relation to tumor angiogenic factor.

Authors:  B R McAuslan; H Hoffman
Journal:  Exp Cell Res       Date:  1979-03-01       Impact factor: 3.905

3.  Quantitative studies of microcirculatory function in malignant tissue: influence of temperature on microvascular hemodynamics during the early growth of the BA 1112 rat sarcoma.

Authors:  B Endrich; B W Zweifach; H S Reinhold; M Intaglietta
Journal:  Int J Radiat Oncol Biol Phys       Date:  1979 Nov-Dec       Impact factor: 7.038

4.  An endotoxin-induced serum factor that causes necrosis of tumors.

Authors:  E A Carswell; L J Old; R L Kassel; S Green; N Fiore; B Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

5.  Angiogenic activity as a marker of neoplastic and preneoplastic lesions of the human bladder.

Authors:  G W Chodak; C Haudenschild; R F Gittes; J Folkman
Journal:  Ann Surg       Date:  1980-12       Impact factor: 12.969

6.  Tumour angiogenesis factor (TAF) and its neutralisation by a xenogeneic antiserum.

Authors:  P Phillips; S Kumar
Journal:  Int J Cancer       Date:  1979-01-15       Impact factor: 7.396

7.  Morphologic effects of antibody to mouse brain endothelium in vivo.

Authors:  M N Hart; L E DeBault; K L Sadewasser; P A Cancilla; E M Henriquez
Journal:  J Neuropathol Exp Neurol       Date:  1981-01       Impact factor: 3.685

8.  Neovasculogenic ability of prostaglandins, growth factors, and synthetic chemoattractants.

Authors:  D BenEzra
Journal:  Am J Ophthalmol       Date:  1978-10       Impact factor: 5.258

9.  An angiogenic factor isolated from tumours: a potent low-molecular-weight compound.

Authors:  J B Weiss; R A Brown; S Kumar; P Phillips
Journal:  Br J Cancer       Date:  1979-09       Impact factor: 7.640

10.  Avascular and vascular phases of tumour growth in the chick embryo.

Authors:  D Knighton; D Ausprunk; D Tapper; J Folkman
Journal:  Br J Cancer       Date:  1977-03       Impact factor: 7.640
View more
  23 in total

1.  Pulmonary nodule characterization: a comparison of conventional with quantitative and visual semi-quantitative analyses using contrast enhancement maps.

Authors:  Iva Petkovska; Sumit K Shah; Michael F McNitt-Gray; Jonathan G Goldin; Matthew S Brown; Hyun J Kim; Kathleen Brown; Denise R Aberle
Journal:  Eur J Radiol       Date:  2006-04-17       Impact factor: 3.528

2.  Quantitative measurement of contrast enhancement of esophageal squamous cell carcinoma on clinical MDCT.

Authors:  Rui Li; Tian-Wu Chen; Li-Ying Wang; Li Zhou; Hang Li; Xiao-Li Chen; Chun-Ping Li; Xiao-Ming Zhang; Ru-Hui Xiao
Journal:  World J Radiol       Date:  2012-04-28

Review 3.  Angiogenesis in brain tumors; pathobiological and clinical aspects.

Authors:  P Wesseling; D J Ruiter; P C Burger
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

Review 4.  Tumor vascular endothelium: barrier or target in tumor directed drug delivery and immunotherapy.

Authors:  G Molema; L F de Leij; D K Meijer
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

Review 5.  New prognostic factors in resectable non-small cell lung cancer.

Authors:  E F Smit; H J Groen; T A Splinter; T Ebels; P E Postmus
Journal:  Thorax       Date:  1996-06       Impact factor: 9.139

6.  Tumor microvasculature targeting with dendrimer-entrapped gold nanoparticles.

Authors:  Rameshwer Shukla; Elliott Hill; Xiangyang Shi; Jinkoo Kim; Maria C Muniz; Kai Sun; James R Baker
Journal:  Soft Matter       Date:  2008       Impact factor: 3.679

Review 7.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

8.  Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor.

Authors:  S W McLeskey; C A Tobias; P R Vezza; A C Filie; F G Kern; J Hanfelt
Journal:  Am J Pathol       Date:  1998-12       Impact factor: 4.307

9.  Cyclic RGD-targeting of reversibly stabilized DNA nanoparticles enhances cell uptake and transfection in vitro.

Authors:  Qing-Hui Zhou; Ye-Zi You; Chao Wu; Yi Huang; David Oupický
Journal:  J Drug Target       Date:  2009-06       Impact factor: 5.121

10.  Recombinant peptides as biomarkers for tumor response to molecular targeted therapy.

Authors:  Ralph J Passarella; Li Zhou; John G Phillips; Hongmei Wu; Dennis E Hallahan; Roberto Diaz
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.